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Edited by Hans-Dieter KlenkAbstract The nucleocapsid (N) protein of SARS coronavirus
(SARS_CoV) is a major structural component of virions, which
appears to be a multifunctional protein involved in viral RNA
replication and translation. Heterogeneous nuclear ribonucleo-
protein A1 (hnRNP A1) is related to the pre-mRNA splicing
in the nucleus and translation regulation in the cytoplasm. In this
report, based on the relevant biophysical and biochemical assays,
the nucleocapsid protein of SARS_CoV (SARS_N) was discov-
ered to exhibit high binding aﬃnity to human hnRNP A1. GST
pull-down results clearly demonstrated that SARS_N protein
could directly and speciﬁcally bind to human hnRNP A1 in vitro.
Yeast two-hybrid assays further indicated in vivo that such bind-
ing relates to the fragment (aa 161–210) of SARS_N and the
Gly-rich domain (aa 203–320) of hnRNP A1. Moreover, kinetic
analyses by surface plasmon resonance (SPR) technology re-
vealed that SARS_N protein has a speciﬁc binding aﬃnity
against human hnRNP A1 with KD at 0.35 ± 0.02 lM (kon =
5.83 ± 0.42 · 103 M1 s1 and koﬀ = 2.06 ± 0.12 · 103 s1). It
is suggested that both SARS_N and hnRNP A1 proteins are pos-
sibly within the SARS_CoV replication/transcription complex
and SARS_N/human hnRNP A1 interaction might function in
the regulation of SARS_CoV RNA synthesis. In addition, the
determined results showed that SARS_N protein has only one
binding domain for interacting with human hnRNP A1, which
is diﬀerent from the mouse hepatitis virus (MHV) binding case
where the nucleocapsid protein of MHV (MHV_N) was found
to have two binding domains involved in the MHV_N/hnRNP
A1 interaction, thereby suggesting that SARS_N protein might
carry out a diﬀerent binding mode to bind to human hnRNP
A1 for its further function performance in comparison with
MHV_N.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Between the end of the year 2002 and June of the year
2003, an atypical pneumonia, referred to as severe acute
respiratory syndrome (SARS) broke out in China and more
than 30 other countries. It has been known that SARS coro-
navirus (SARS_CoV) is responsible for SARS infection [1–
4], and further research showed that SARS_CoV belongs
to one member of the Coronaviridae and is moderately re-
lated to the other known coronaviruses [5]. SARS_CoV
has 11 open reading frames (ORFs) that encode 23 putative
proteins including four major structural proteins: nucleocap-
sid (N), spike (S), membrane (M), and small envelope (E)
proteins [5,6]. The N protein of SARS_CoV (SARS_N) is
a highly basic structural protein localized in the cytoplasm
and the nucleolus of Trichoplusia ni BT1 Tn 5B1-4 cells
[7]. Previous studies have indicated that the N proteins of
other coronaviruses are extensively phosphorylated and asso-
ciated with viral RNA to form a helical ribonucleoprotein
(RNP) that comprises the viral core structure [8]. Recently,
we discovered the fact that SARS_N tightly binds to human
cyclophilin A, which might provide a new hint in under-
standing the possible SARS_CoV infection pathway against
human cell [9].
SARS_N is a 422 amino acid protein, which shares 20–30%
homology with the N proteins of some other coronaviruses
[5,6]. It was reported that the nucleocapsid protein of MHV
(MHV_N) binds to the tandemly repeated sequence
(UCYAAC) of the viral genome according to the SRXX re-
peated region (aa 177–231) [10]. On the other hand, the gen-
ome sequence analysis for SARS_CoV has revealed that the
transcription-regulating sequences at 5 0 end of each gene in-
volve such partially conserved core sequence [5]. Structurally,
SARS_N owns the SRXX repeated region that shares high
similarity with that of MHV_N protein according to the se-
quence analysis. Therefore, SARS_N is predicted to interact
with the viral RNA and be involved in the mRNA synthesis
and transcription of SARS_CoV.
In human cells, it has been discovered that there are more
than 20 heterogeneous nuclear ribonucleoproteins (hnRNPs),
and hnRNP A1 is the best-characterized protein that is most
likely related to pre-mRNA splicing and transport of cellular
RNAs [11]. Research has indicated that hnRNP A1 behaves
as a global regulator of alternative pre-mRNA splicing by
antagonizing the activities of several serine/arginine-rich splic-
ing factors (SR protein), thus resulting in the activation ofblished by Elsevier B.V. All rights reserved.
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exons [12]. In structure, hnRNP A1 contains two RNA-bind-
ing domains (RBDs) and a glycine-rich domain that is respon-
sible for protein–protein interaction. hnRNP A1 selectively
interacts through its gly-rich domain with diﬀerent RNA-bind-
ing proteins, especially some splicing factors (SR proteins)
[13,14]. It was proved that hnRNP A1 was involved in MHV
RNA replication and transcription, certainly regulating
RNA synthesis of a cytoplasmic virus [11]. A recently pub-
lished paper demonstrated that the nucleocapsid protein of
MHV could interact with hnRNP A1 [15]. Since SARS_N is
able to bind to RNA [16] and also shares some homology with
MHV_N, we think that during the SARS_CoV life cycle
SARS_N might also possibly interact with human hnRNP
A1 for mRNA synthesis and mature mRNA transporting
and transcription.
In the current study, by use of GST pull-down, yeast two-hy-
brid and SPR techniques we have discovered that SARS_N
could directly interact with human hnRNP A1 both in vitro
and in vivo. The results indicated that SARS_N/human
hnRNP A1 interaction involves the SR-rich fragment (aa
161–210) of SARS_N and the Gly-rich domain (aa 203–320)
of hnRNP A1, which thereby suggests that both SARS_N
and human hnRNP A1 proteins are possibly within the
SARS_CoV replication/transcription complex, and their inter-
action might function in the regulation of SARS_CoV RNA
synthesis similar to the MHV_N case. In addition, the fact that
there is only one hnRNP A1-binding domain for SARS_N has
suggested that SARS_N protein binds to hnRNP A1 in
SARS_CoV taking a diﬀerent mode in comparison with
MHV_N.Table 1
Primers for the truncated fragments of SARS_N used in yeast two-
hybrid
DN1 (sense) GGTTGAATTCCCAGATGACCAAATTGGCTACTACC
DN2 (sense) GGTTGAATTCCAACTTCCTCAAGGAACAACATTGCC
DN3(DN5) (sense) AATTGAATTCATGGCTAGCGGAGGTGGTGAAA
DN4 (sense) GCGTGAATTCGACCTAATCAGACAAGGAACTGA
DN5 (anti-sense) GGCCGGATCCTTAGTTGTCTTTGAATTGTGGAT
DN2 0 (anti-sense) GGAAGGATCCTTATAGCACGGTGGCAGCATTGT
DN3 0 (anti-sense) GGAAGGATCCTTATCGAGCAGGAGAATTTCCCC2. Materials and methods
2.1. Chemicals
The gluthatione S-transferase (GST) aﬃnity resin and the molecular
weight marker were purchased from Amersham Pharmacia Biotech,
Inc. IPTG was purchased from Promega. Yeast nitrogen base without
amino acids, yeast synthetic drop-out medium supplement without
tryptophan, yeast synthetic drop-out medium supplement without leu-
cine and tryptophan, yeast synthetic drop-out medium supplement
without leucine, tryptophan and histidine were all purchased from Sig-
ma Chemical Co. The 3-amino-10,2 0,4 0-triazole was from Sangon. All
other chemicals were from Sigma in their analytical grade.
2.2. Cloning, expression and puriﬁcation of GST-tagged human hnRNP
A1
The gene for human hnRNP A1 (Gene Bank Accession #BC070315)
was ampliﬁed by PCR from a cDNA library of Hela cells. Primers for
the ampliﬁcation were 5 0 ATGTCTAAGTCAGAGTCTCCTAAA-
GAGCCGAAC 3 0 and 5 0 TTAAAATCTTCTGCCACTGCCATAG-
CTACTGC 3 0. The ampliﬁed products were cloned into pGEM-T
Easy Vector (Promega) according to the standard Promega manual
(No. 042) and sequenced. The gene in pGEM-T Easy Vector was
ampliﬁed by PCR using the primers 5 0 GGCTGGATCCATGTC-
TAAGTCAGAGTCTCCTA 3 0 and 5 0 GGTCGAATTCTTAAAAT-
CTTCTGCCACTGCCATA 3 0. The ampliﬁed product was digested
with BamHI and EcoRI (underlined in the primer) then ligated with
pGEX4T-1 (Amersham Pharmacia Biotech) digested with the same
restriction enzymes. The pGEX4T-1-hnRNP A1 vector was trans-
formed into BL21 (DE3) Escherichia coli (Novagen). Overnight cul-
tures of a single colony per 10 ml of LB medium containing 100 lg/ml
ampicillin were diluted to 1:10 with the same medium. After 3 h
when the OD600 reached 0.7, expression of the protein was induced
by the addition of 0.5 mM IPTG, and cultures were incubated for
5 h at 22 C with aeration. Cells were recovered by centrifugation,quick-frozen, and stored overnight at 80 C. Frozen cells were
thawed, resuspended in 15 ml of the PBS buﬀer (140 mM NaCl,
2.7 mM KCl, 10 mM Na2HPO4, and 1.8 mM KH2PO4, pH 7.4) con-
taining 5 mM EDTA and 5 mM b-mercaptoethanol per gram of cells,
and then lysed by sonication for 20 min in ice bath. The lysate was
cleared by centrifugation, and the supernatant was loaded onto a glu-
tathione-column (Amersham Pharmacia) equilibrated with PBS buﬀer.
The loaded column was washed by 200 ml PBS buﬀer at 4 C. GST-
hnRNP A1 was eluted using 10 mM reduced glutathione freshly added
to PBS buﬀer. The glutathione contained with the puriﬁed protein was
removed by dialysis against PBS buﬀer. The puriﬁed protein was de-
tected as a single band on SDS–PAGE gel, and protein concentration
was measured by the absorbance at 280 nm using the extinction coef-
ﬁcient of 66990 l/mol/cm.
2.3. Expression and puriﬁcation of His-tagged SARS_N
The recombinant nucleocapsid protein of SARS coronavirus
(SARS_N) was cloned, expressed and puriﬁed according to the pub-
lished procedure reported by Luo et al. [17].
2.4. GST pull-down assay
GST pull-down assay was performed using the ProFounde Pull-
Down GST Protein: Protein Interaction Kit (Pierce). The puriﬁed
GST-hnRNP A1 was adsorbed onto 60 ll Glutathione–Sepharose
beads, equilibrated with BupHe TBS buﬀer (25 mM Tris–HCl and
0.15 M NaCl, pH 7.2) in a Handeee Mini-spin column, and served
as bait proteins in the subsequent steps. After 4 h at 4 C, the beads
carrying GST fusion hnRNP A1 were resuspended in 400 ll 1:1 wash
solution of TBS: ProFounde lysis buﬀer for 4 times. After addition of
0.5 mg of the puriﬁed SARS_N as prey protein, the mixtures were
gently shaken for 3 h at 4 C and left for an additional 30 min without
mixing. The rinsing was repeated for 5 times using 400 ll of wash solu-
tion as mentioned above. The bound proteins were eluted by 100 mM
of glutathione elution buﬀer. The eluted samples were analyzed by
SDS–PAGE.
2.5. Recombinant vectors construction for yeast two-hybrid assay
The yeast vectors of pGADT7 and pGBKT7 were obtained from
Clontech (Palo Alto, CA). The hnRNP A1 gene was ampliﬁed with
the following primers: 5 0 GGCGGAATTCATGTCTAAGTCA-
GAGTCTCCTA 3 0 and 5 0 GGTCGGATCCTTAAAATCTTCT-
GCCACTGCCATA 3 0. The ampliﬁed products were digested with
EcoRI and BamHI (NEB, USA) then cloned into the pGADT7 vector
between the two sites. To conﬁrm that the Gly-rich domain of hnRNP
A1 was involved in hnRNP A1/SARS_N interaction, the fragment
1–606 of hnRNP A1 was also cloned into pGADT7 vector by the
same above-mentioned method. The primers for this cloning were:
5 0 GGCCGAATTCATGTCTAAGTCAGAGTCTCCTAA 3 0 and 5 0
GGCTGGATCCTTAAAAGTTTCCAGAACCACTTC 3 0.
The SARS_N gene was ampliﬁed with the following primers: 5 0
GGGTGAATTCATGTCTGATAATGGACCCCAAT 3 0 and 5 0
AATTGGATCCTTATGCCTGAGTTGAATCAGCAG 3 0. The
ampliﬁed products were digested with EcoRI and BamHI (NEB) then
cloned into pGBKT7 vector. To identify the putative domain of amino
acid sequence required for hnRNP A1/SARS_N interaction, diﬀerent
fragments of SARS_N gene were prepared by PCR. The anti-sense
primers for DN1, DN2, DN3 and DN4 and the sense primers for
DN2 0 and DN3 0 were the same as those for full-length SARS_N gene
cloning as mentioned above. Other primers are listed in Table 1.
Fig. 1. SARS_N/human hnRNP A1 interaction determined by GST
pull-down. Samples were analyzed on a 10% SDS–polyacrylamide gel,
and the band was visualized with Coomassie brilliant blue. Compo-
nents in each lane are shown at the top. Lane 1, molecular mass
marker; lane 2, puriﬁed His-tagged SARS_N; lane 3, puriﬁed GST-
tagged human hnRNP A1; lane 4, agarose gel control; lane 5, human
hnRNP A1 and the pull-down SARS_N.
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Competent cells of yeast strain AH109 were obtained from clontech
(Plano Alto, CA). Transformations were performed according to the
manufacturers protocol. Brieﬂy, 500 ng of plasmid DNA was added
to 50 ml of competent cells and mixed again with 300 ml lithium ace-
tate at 30 C for 30 min followed by heat-shock at 42 C for 30 min
and subsequently spread on a drop-out-agar plate in the absence of
leucine and tryptophan. The plates were incubated at 30 C for 48 h
for yeast growth. PCR was used to conﬁrm transformation with the
target gene. A positive clone was inoculated in the SD medium lacking
leucine, typtophan and histidine (SD-LTH) and supplemented with
10 mM 3-amino-10,2 0,4 0-triazole (SD-LTH + 3-AT). The medium was
shaken at 200 rpm at 30 C for 96 h before 400 ll of the medium
was ﬁlled into the well of a 96-well microplate. The absorbance at
595 nm of the medium in the 96-well microplate was measured in a
TECAN reader (Switzerland). This is an alternative method based
on the growth curve analysis for yeast culture that is amenable to
microtiter plate format. The method used here is reproducible and of
equal or greater sensitivity compared with the b-galactosidase assay
[18]. All the yeast media were prepared according to the standard
Protocols Handbook (PT3024-1, Clontech).
2.7. Surface plasmon resonance technology based analysis
SPR technology based Biacore 3000 (Biacore AB) biosensor was
used to perform the kinetic analysis of SARS_N/human hnRNP A1
interaction. CM5 research grade sensor chips and P20 were purchased
from Biacore AB. N-Hydroxysuccinimide, N-ethy-N 0-(3-diethylamino-
propyl)carbodiimide, and ethanolamine coupling regents were used to
immobilize the ligand to the sensor surface using a standard amine-
coupling procedure. The running and sample buﬀers were 10 mM
HEPES, pH 7.4, containing 150 mM NaCl, and all the buﬀers were ﬁl-
tered and degassed before use. The analyte was injected (120 s, 30 ll/s)
followed by a dissociation phase (120 s). Each experiment was repeated
at least twice, and the data were obtained at 25 C. The association
rate (kon), dissociation rate (koﬀ), and equilibrium dissociation (KD,
KD = koﬀ/kon) constants were obtained from each sensorgram by ﬁtting
to 1:1 Langmuir binding model using a global ﬁtting method from the
BIAevaluation 3.1 software. The binding aﬃnity of the synthesized
peptide (ASSRSSSRSRGNSRN) to the human hnRNP A1 was calcu-
lated by steady-state ﬁtting mode in the BIAevaluation 3.1 software. In
the inhibitory assays, the peptide with varied concentrations was mixed
with 30 lM human hnRNP A1 for 2 h before injection to Biacore
3000.3. Results
3.1. GST pull-down assay directly revealed SARS_N/human
hnRNP A1 interaction
In order to identify the interaction between hnRNP A1 and
SARS_N, the recombinant human GST-hnRNP A1 protein
was over-expressed in E. coli, followed by puriﬁcation using
Glutathione–Sepharose aﬃnity beads. SARS_N/human
hnRNP A1 interaction was then determined by GST pull-
down assay, in which the puriﬁed human GST-hnRNP A1
(Fig. 1, lane 3) protein was immobilized on the Glutathione–
Sepharose beads as a bait protein according to the kit. The
His-tagged SARS_N protein as the prey was puriﬁed through
a Ni aﬃnity column (Fig. 1, lane 2). After the GST-hnRNP A1
and the possible partner were eluted by glutathione, the sam-
ples were analyzed by SDS–PAGE. As indicated in lane 5 of
Fig. 1, SARS_N protein could be also detected on the SDS–
PAGE, suggesting that human GST-hnRNP A1 was eluted
by glutathione together with SARS_N protein. SARS_N bind-
ing to human hnRNP A1 could be considered to be speciﬁc be-
cause the bead itself did not pull down any SARS_N protein as
shown in lane 4. All these results thereby determined that
SARS_N protein could speciﬁcally bind to human hnRNP
A1 in vitro.3.2. Real-time analysis of SARS_N/human hnRNP A1
interaction by Biacore 3000
We employed Biacore 3000 as an alternative approach to
perform the kinetic analysis of SARS_N/human hnRNP A1
interaction. During the assay, SARS_N protein was immobi-
lized on the CM5 sensor chip as ligand in 2000 RU according
to the standard amine-coupling wizard. The control ﬂow cell
was activated then blocked directly without immobilizing
any protein to eliminate non-speciﬁc interaction between
hnRNP A1 and the sensor chip surface. The puriﬁed human
hnRNP A1 protein was prepared in a series of concentrations
as analyte then injected into Biacore 3000. The binding level
(measured in RU) of human hnRNP A1 to the immobilized
SARS_N rose and reached saturation with the increasing con-
centration (Fig. 2A), which demonstrated again that human
hnRNP A1 protein can directly bind to SARS_N in vitro.
The association of SARS_N with hnRNP A1 could be de-
scribed in a simple equilibrium: Aþ B() AB. The kinetic
parameters (the equilibrium dissociation constant, KD; associ-
ation rate constant, kon; and dissociation rate constant, koﬀ) of
the SARS_N/hnRNP A1 protein–protein interaction were
determined by the 1:1 Langmuir binding model. As such, the
evaluated curves were found to ﬁt the experimental curves very
well (Fig. 2A) and the ﬁtting reliability was also reﬂected by
the small chi2 and residuals (Fig. 2B). The KD for SARS_N/
hnRNP A1 interaction was thus simulated as 0.35 ± 0.02 lM
with kon = 5.83 ± 0.42 · 103 M1 s1 and koﬀ = 2.06 ±
0.12 · 103 s1, which quantitatively revealed the high binding
aﬃnity of SARS_N against human hnRNP A1.
3.3. SARS_N/hnRNP A1 interaction validation and interaction
region mapping by yeast two-hybrid assay
To further validate the SARS_N/hnRNP A1 interaction,
the yeast two-hybrid assay technology was performed. The
full-length SARS_N protein and human hnRNP A1 were
cloned in-frame into pGBKT7 (pGBKT7-N) and pGADT7
Fig. 2. Sensorgrams of human hnRNP A1 binding to the immobilized
SARS_N. The binding curves were ﬁtted to 1:1 Langmuir binding
model. Superposition of ﬁtting curves (in black) to original curves (in
grey) (A) and the small residuals (B) demonstrates the goodness of the
ﬁtting.
Fig. 3. Mapping the interaction domain of SARS_N. Schematic
description of the truncated fragments (A) and the yeast two-hybrid
assay results for SARS_N/human hnRNP A1 interactions in their
truncated and non-truncated forms (B). The empty vectors pGBKT7
and pGADT7 co-transformed were used as the negative control.
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mid constructs into AH109, a phenotype was observed on high
stringency nutrition medium (SD-LTH + 10 mM 3-AT) (Fig.
3B) even on higher stringency (30 mM 3-AT) (data not
shown), which therefore indicated the possible presence of
SARS_N/hnRNP A1 interaction in vivo. Moreover, the fact
that the control with empty plasmid did not show cell growth
(Fig. 3B) further suggests that the SARS_N/hnRNP A1 inter-
action might be relatively speciﬁc in yeast.
To map the involved regions of SARS_N within the
SARS_N/hnRNP A1 interaction, a series of 5 nested frag-
ments of SARS_N were generated (Fig. 3A). These fragments,
designated from DN1 to DN5, were cloned into pGBKT7 vec-
tor, and then co-transformed respectively with pGADT7-
hnRNP A1 into the AH109 yeast cell. After 96-h growth in
high stringency nutrition medium (SD-LTH + 10 mM 3-AT)
at 30 C with shaking, 300 ll cells were transferred into the
96-well microplate. The growth curves of these cells were then
evaluated by measuring their absorbance at 595 nm in the 96-
well microplate. As indicated in Fig. 3B, DN1 (aa 81–422) and
DN2 (aa 161–422) showed viability compared to the empty
control, thus suggesting that these two segments of SARS_N
protein have binding aﬃnities to human hnRNP A1. It is
noted that deletion of the fragment from aa 1 to 211 of
SARS_N resulted in the loss of its binding activity to human
hnRNP A1 as indicated by the fact that no viability was de-
tected for DN3 (aa 211–422), DN4 (aa 291–422) and DN5 (aa
211–350). This therefore suggested that the interacting frag-
ment of SARS_N protein involved in the SARS_N/human
hnRNP A1 interaction is most probably within the segment
of aa 1–211. In addition, it is found that the growths of both
DN1 (aa 81–422) and DN2 (aa 161–422) are close to each other
but a little less than that of the full-length N, it seems that the
N terminal 80 amino acid residues of SARS_N might be in-
volved in SARS_N/hnRNP A1 interaction. To validate this
possibility, we made two truncated fragments for SARS_N,
DN2 0 (aa 1–160) and DN3 0 (aa 1–210). As indicated in Fig.3B, DN2 0 had no binding aﬃnity to human hnRNP A1, while
DN3 0 could bind to human hnRNP A1, which thereby indi-
cates that the N terminal 80aa fragment does not participate
in the SARS_N/human hnRNP A1 interaction and the seg-
ment of aa 161–210 of SARS_N is indispensable for this pro-
tein–protein interaction.
To explore the possible binding fragment of human hnRNP
A1 within the SARS_N/hnRNP A1 interaction, a C-terminus-
deleted fragment, DA1 (aa 1–202) of human hnRNP A1 was
studied. This fragment was cloned into pGADT7 plasmid
(pGADT7-DA1) then co-transformed with pGBKT7-N into
AH109. As shown in Fig. 3B, the yeast cell containing
pGADT7-DA1 and pGBKT7-N showed no viability (lane
DA1 + N), suggesting that DA1 (aa 1–202) of hnRNP A1
might not interact with SARS_N. Since a lot of facts have con-
ﬁrmed that hnRNP A1 protein interacts selectively through its
C-terminal Gly-rich domain with diﬀerent RNA-binding pro-
teins [12], together with our result, it is suggested that the C-
terminal Gly-rich domain of human hnRNP A1 may be also
involved in the SARS_N/human hnRNP A1 interaction.
3.4. SRXX-repeat domain of SARS_N contributes to SARS_N/
hnRNP A1 interaction
It is noticed that there is an SRXX-repeat section within
the fragment aa 161–210 of SARS_N, and this SRXX-repeat
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ing proteins [12,13]. It has been reported that this SRXX-
repeat fragment of MHV_N is within the MHV_N/hnRNP
A1 interaction parts [15]. Therefore, encouraged by these
facts, we supposed that the SRXX-repeat fragment of
SARS_N might be also involved in the SARS_N/hnRNP
A1 interaction. To validate this hypothesis, we synthesized
the peptide (ASSRSSSRSRGNSRN) according to the frag-
ment aa 183–197 of SARS_N and applied it to Biacore as-
say. The curves of this peptide binding to the immobilized
GST-hnRNP A1 (ﬂow cell was immobilized with GST as
control) were shown in Fig. 4A. The binding aﬃnity of this
peptide to the human hnRNP A1 protein was thus evaluated
as KD at 148 ± 12 lM by the steady-state ﬁt model. To fur-
ther conﬁrm this speciﬁc binding of this SARS_N SRXX-re-
peat domain to hnRNP A1, we also performed an inhibitory
experiment by using this peptide to inhibit hnRNP A1 inter-
action with the immobilized SARS_N protein through Bia-
core 3000. As shown in Fig. 4B, 100 and 625 lM of this
peptide did perturb 10 lM hnRNP A1 binding to SARS_N
protein, which thereby suggested that the SRXX-repeat frag-
ment of SARS_N does contribute to the SARS_N/human
hnRNP A1 interaction.Fig. 4. Interaction of the peptide (ASSRSSSRSRGNSRN) with
human hnRNP A1 (A), and the peptide inhibition assay against the
human hnRNP A1/SARS_N interaction (B).4. Discussion
In the present study, by employing a series of biochemical
and biophysical methods, we have ﬁrstly reported that
SARS_N protein has a speciﬁc binding aﬃnity to human
hnRNP A1, and the further yeast two-hybrid assay demon-
strated that the C-terminus of human hnRNP A1 and the frag-
ment aa 161–210 of SARS_N probably contribute to the
SARS_N/human hnRNP A1 interaction. Since both human
hnRNP A1 and SARS_N proteins bind to RNA and imple-
ment their functions in RNA replication and transcription
[11], we thus tentatively proposed that, together with the
bound RNA, SARS_N might probably interact with the hu-
man hnRNP A1 to form a complex in the regulation of the
transcription and replication of SARS_CoV according to
the reported model for MHV [11]. Therefore, it seems that
the cross talk between human hnRNPA1 and SARS_N protein
might be essential for SARS_CoV replication and transcrip-
tion. Additionally, SARS_N protein binds to the C-terminus
of human hnRNP A1 and cooperates with hnRNP A1 to re-
cruit more proteins in forming the transcription or replication
complex. As such, the C-terminal-deletion mutant of human
hnRNP does not interact with SARS_N and fails to bring it
into the initiation complex, possibly resulting in the failure of
SARS-CoV RNA replication and transcription.
In addition, the yeast two-hybrid result has clearly indicated
that only one fragment of SARS_N (aa 161–211) is required
for SARS_N/human hnRNP A1 interaction, which is diﬀerent
from the MHV_N case where MHV_N has two domains, aa
1–292 and aa 392–455 that are involved in its binding to
hnRNP A1 [15] (Fig. 5), suggesting that MHV_N/hnRNP
A1 interaction seems to be stronger in comparison with
SARS_N/hnRNP A1. As we know, the fragment aa 161–211
contains SRXX-repeat domain that is multifunctional and
conserved in N protein of coronaviruses [19]. In this work,
the fact that the synthesized SRXX-repeat peptide has weak
binding aﬃnity (KD = 148 ± 12 lM) to human hnRNP A1
(Fig. 2A) suggests that the SRXX-repeat segment of SARS_
Nis involved in but does not dominate the SARS_N/human
hnRNP A1 interaction, which is also within the similar binding
feature of this corresponding fragment in MHV_N (Fig. 5).
Interestingly, it has been recently reported that SRXX-repeat
fragment is indispensable for SARS_N multimerization [20]
and for SARS_N interaction with SARS_CoV membrane pro-
tein [19]. All these facts have indicated that SRXX-repeat frag-
ment of SARS_N protein might play a potent role in
SARS_CoV infection, even though more studies should be ad-
dressed in exploring how SARS_N regulates itself to adapt its
interaction with the diﬀerent partners.Fig. 5. Comparison of the human hnRNP A1-binding fragments (the
part in frame) in SARS_N with MHV_N.
2628 H. Luo et al. / FEBS Letters 579 (2005) 2623–2628In conclusion, our data have shown for the ﬁrst time both in
vitro and in vivo that the nucleocapsid protein of SARS coro-
navirus has a high binding aﬃnity to human hnRNP A1, and
such a protein–protein interaction involves the region aa 161–
210 of SARS_N and the C-terminus aa 203–320 of human
hnRNP A1. Based on the analytical results for MHV, it is sug-
gested that both SARS_N and human hnRNP A1 proteins
might be among the SARS_CoV replication/transcription
complex and their interaction may be involved in the regula-
tion of SARS_CoV RNA synthesis. The fact that there is only
one instead of two human hnRNP A1-binding domain in
SARS_N indicates that the SARS_N protein interaction with
human hnRNP A1 for SARS_CoV might take a diﬀerent bind-
ing type compared with that for MHV, which is possibly due
to the low sequence homology for SARS_CoV relative to other
coronaviruses.
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